Current Report Filing (8-k)
August 18 2020 - 04:57PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 18,
2020
ALBIREO PHARMA, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation) |
|
001-33451
(Commission File
Number) |
|
90-0136863
(IRS Employer
Identification No.) |
10
Post Office Square, Suite 502 South
Boston, Massachusetts
(Address of principal executive offices) |
|
02109
(Zip Code) |
(857) 254-5555
Registrant’s telephone number, including area code
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
¨ |
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
¨ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the
Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which
registered |
|
Common
Stock |
|
ALBO |
|
The
Nasdaq Capital Market |
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
¨
Item 8.01 Other Events.
On August 18, 2020, Albireo Pharma, Inc. issued a press
release announcing topline results from the Phase 2
proof-of-concept clinical trial evaluating elobixibat, its ileal
bile acid transporter (IBAT) inhibitor currently approved in Japan
for chronic constipation, for the treatment of nonalcoholic fatty
liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). A
copy of the press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
ALBIREO
PHARMA, INC. |
|
|
|
|
Date:
August 18, 2020 |
/s/
Ronald H.W. Cooper |
|
Ronald
H.W. Cooper |
|
President
and Chief Executive Officer |
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Dec 2020 to Jan 2021
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Jan 2020 to Jan 2021